Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis

Case report: Dupilumab treatment improved type 2 disorders in a patient with IPEX syndrome diagnosis

We described a case of IPEX syndrome successfully controlled with dupilumab, an anti-IL4 receptor alpha subunit inhibitor. IPEX syndrome is a rare and generally fatal genetic disorder characterized by immune dysregulation, polyendocrinopathy and enteropathy, mostly diagnosed in early childhood. None...

Full description

Bibliographic Details
Main Authors: C. Caruso, L. Laterza, C. R. Settanni, S. Colantuono, C. Di Mario, B. Tolusso, F. Castrì, E. Gremese, F. Scaldaferri, A. Armuzzi, C. De Simone, K. Peris, A. Chiricozzi, A. Gasbarrini
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Immunology
Subjects:
cytokines
atopic dermatis
type2
biomarker
dupilumab
IPEX (immune dysregulation
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2022.995304/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2022.995304/full

Similar Items